Carmat S.A.
CKMTF
Other OTC12.75
USD
-13.25
- -
Carmat S.A.
CKMTF
(Other OTC)
Recent
price
12.75
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Carmat SA (CKMTF) develops, manufactures, and commercializes Aeson, a total artificial heart designed as a long-term therapy for patients suffering from end-stage biventricular heart failure who are not eligible for a heart transplant; the company also provides related surgical training, patient monitoring services, and post-implant support through its proprietary software platform. Founded in 2008 and headquartered in Vélizy-Villacoublay, France, Carmat operates primarily in the medical device sector, targeting cardiovascular patients across Europe, the United States, and select international markets, with regulatory approvals including CE marking in Europe and ongoing FDA trials in the US. The company's product pipeline focuses on hybrid bio-prosthetic technology combining bovine pericardial tissue and electro-mechanical actuators to mimic natural heart function, serving hospitals, transplant centers, and cardiothoracic surgeons as key customers. In recent developments within the last two years, Carmat secured additional funding through a 45 million euro capital increase in 2024 and formed strategic partnerships with distribution allies in Japan and the Middle East to expand commercialization; it also reported successful implantation milestones exceeding 100 patients worldwide by mid-2025 and launched manufacturing scale-up initiatives at its French facility to meet growing demand.